BRISTOL-MYERS SQUIBB COMPANY Cash and Cash Equivalents, Period Increase (Decrease)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Cash and Cash Equivalents, Period Increase (Decrease) of $23.58 billion for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-10-31.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-10-31
- BRISTOL-MYERS SQUIBB COMPANY cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $2.08B, a 409.78% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $21.07B.
- BRISTOL-MYERS SQUIBB COMPANY cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $424.00M.
- BRISTOL-MYERS SQUIBB COMPANY cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $1.50B, a 93.44% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY cash and cash equivalents, period increase (decrease) for fiscal 2018 was $1.49B, a 25.84% increase from fiscal 2017.
- BRISTOL-MYERS SQUIBB COMPANY cash and cash equivalents, period increase (decrease) for fiscal 2017 was $1.18B, a 36.07% decline from fiscal 2016.
- BRISTOL-MYERS SQUIBB COMPANY cash and cash equivalents, period increase (decrease) for fiscal 2016 was $1.85B.
- BRISTOL-MYERS SQUIBB COMPANY cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$3.19B, a 260.50% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-09-30 | $2.08B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $23.15B derived: sum of 2 quarters · filed 2019-10-31 | $23.58B 10-Q · filed 2019-10-31 | $25.08B derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-06-30 | $21.07B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | $21.49B 10-Q · filed 2019-07-25 | $23.00B derived: sum of 3 quarters · filed 2019-07-25 | $23.41B derived: sum of 4 quarters · filed 2019-10-31 |
| 2019-03-31 | $424.00M 10-Q · filed 2019-04-25 | $1.93B derived: sum of 2 quarters · filed 2019-04-25 | $2.34B derived: sum of 3 quarters · filed 2019-10-31 | $1.99B derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-12-31 | $1.50B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $1.91B derived: sum of 2 quarters · filed 2019-10-31 | $1.57B derived: sum of 3 quarters · filed 2019-10-31 | $1.49B 10-K · filed 2019-02-25 |
| 2018-09-30 | $409.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $66.00M derived: sum of 2 quarters · filed 2019-10-31 | -$13.00M 10-Q · filed 2019-10-31 | $764.00M derived: sum of 4 quarters · filed 2019-10-31 |
| 2018-06-30 | -$343.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-25 | -$422.00M 10-Q · filed 2019-07-25 | $355.00M derived: sum of 3 quarters · filed 2019-07-25 | $1.53B derived: sum of 4 quarters · filed 2019-07-25 |
| 2018-03-31 | -$79.00M 10-Q · filed 2019-04-25 | $698.00M derived: sum of 2 quarters · filed 2019-04-25 | $1.87B derived: sum of 3 quarters · filed 2019-04-25 | $1.43B derived: sum of 4 quarters · filed 2019-04-25 |
| 2017-12-31 | $777.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $1.95B derived: sum of 2 quarters · filed 2019-02-25 | $1.51B derived: sum of 3 quarters · filed 2019-02-25 | $1.18B 10-K · filed 2019-02-25 |
| 2017-09-30 | $1.17B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $734.00M derived: sum of 2 quarters · filed 2018-10-25 | $407.00M 10-Q · filed 2018-10-25 | $1.21B derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | -$440.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | -$767.00M 10-Q · filed 2018-07-26 | $38.00M derived: sum of 3 quarters · filed 2019-02-25 | $536.00M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | -$327.00M 10-Q · filed 2018-04-26 | $478.00M derived: sum of 2 quarters · filed 2019-02-25 | $976.00M derived: sum of 3 quarters · filed 2019-02-25 | $1.27B derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $805.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $1.30B derived: sum of 2 quarters · filed 2019-02-25 | $1.59B derived: sum of 3 quarters · filed 2019-02-25 | $1.85B 10-K · filed 2019-02-25 |
| 2016-09-30 | $498.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-26 | $788.00M derived: sum of 2 quarters · filed 2017-10-26 | $1.05B 10-Q · filed 2017-10-26 | -$543.00M derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $290.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $549.00M 10-Q · filed 2017-07-27 | -$1.04B derived: sum of 3 quarters · filed 2018-02-13 | -$1.26B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $259.00M 10-Q · filed 2017-04-27 | -$1.33B derived: sum of 2 quarters · filed 2018-02-13 | -$1.55B derived: sum of 3 quarters · filed 2018-02-13 | -$3.65B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | -$1.59B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-13 | -$1.81B derived: sum of 2 quarters · filed 2018-02-13 | -$3.91B derived: sum of 3 quarters · filed 2018-02-13 | -$3.19B 10-K · filed 2018-02-13 |
| 2015-09-30 | -$224.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | -$2.32B derived: sum of 2 quarters · filed 2016-10-27 | -$1.60B 10-Q · filed 2016-10-27 | -$876.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | -$2.10B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | -$1.37B 10-Q · filed 2016-07-28 | -$652.00M derived: sum of 3 quarters · filed 2017-02-21 | -$83.00M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $723.00M 10-Q · filed 2016-04-28 | $1.44B derived: sum of 2 quarters · filed 2017-02-21 | $2.01B derived: sum of 3 quarters · filed 2017-02-21 | $1.07B derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $720.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $1.29B derived: sum of 2 quarters · filed 2017-02-21 | $346.00M derived: sum of 3 quarters · filed 2017-02-21 | $1.99B 10-K · filed 2017-02-21 |
| 2014-09-30 | $569.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | -$374.00M derived: sum of 2 quarters · filed 2015-10-27 | $1.26B 10-Q · filed 2015-10-27 | $3.08B derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$943.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-23 | $696.00M 10-Q · filed 2015-07-23 | $2.51B derived: sum of 3 quarters · filed 2016-02-12 | $2.46B derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $1.64B 10-Q · filed 2015-04-28 | $3.45B derived: sum of 2 quarters · filed 2016-02-12 | $3.40B derived: sum of 3 quarters · filed 2016-02-12 | $3.87B derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $1.81B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $1.76B derived: sum of 2 quarters · filed 2016-02-12 | $2.23B derived: sum of 3 quarters · filed 2016-02-12 | $1.93B 10-K · filed 2016-02-12 |
| 2013-09-30 | -$50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-24 | $416.00M derived: sum of 2 quarters · filed 2014-10-24 | $115.00M 10-Q · filed 2014-10-24 | $268.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $466.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-24 | $165.00M 10-Q · filed 2014-07-24 | $318.00M derived: sum of 3 quarters · filed 2015-02-13 | -$980.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | -$301.00M 10-Q · filed 2014-04-29 | -$148.00M derived: sum of 2 quarters · filed 2015-02-13 | -$1.45B derived: sum of 3 quarters · filed 2015-02-13 | -$952.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $153.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | -$1.15B derived: sum of 2 quarters · filed 2015-02-13 | -$651.00M derived: sum of 3 quarters · filed 2015-02-13 | -$4.12B 10-K · filed 2015-02-13 |
| 2012-09-30 | -$1.30B derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-23 | -$804.00M derived: sum of 2 quarters · filed 2013-10-23 | -$4.27B 10-Q · filed 2013-10-23 | -$2.97B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-06-30 | $494.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | -$2.98B 10-Q · filed 2013-07-25 | -$1.67B derived: sum of 3 quarters · filed 2014-02-14 | -$864.00M derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-03-31 | -$3.47B 10-Q · filed 2013-04-25 | -$2.16B derived: sum of 2 quarters · filed 2014-02-14 | -$1.36B derived: sum of 3 quarters · filed 2014-02-14 | -$1.10B derived: sum of 4 quarters · filed 2014-02-14 |
| 2011-12-31 | $1.30B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-14 | $2.11B derived: sum of 2 quarters · filed 2014-02-14 | $2.37B derived: sum of 3 quarters · filed 2014-02-14 | $743.00M 10-K · filed 2014-02-14 |
| 2011-09-30 | $806.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $1.07B derived: sum of 2 quarters · filed 2012-10-24 | -$562.00M 10-Q · filed 2012-10-24 | -$3.11B derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $260.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | -$1.37B 10-Q · filed 2012-07-25 | -$3.92B derived: sum of 3 quarters · filed 2013-02-15 | -$2.25B derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | -$1.63B 10-Q · filed 2012-04-26 | -$4.18B derived: sum of 2 quarters · filed 2013-02-15 | -$2.51B derived: sum of 3 quarters · filed 2013-02-15 | -$1.73B derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | -$2.55B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | -$885.00M derived: sum of 2 quarters · filed 2013-02-15 | -$102.00M derived: sum of 3 quarters · filed 2013-02-15 | -$2.65B 10-K · filed 2013-02-15 |
| 2010-09-30 | $1.66B derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $2.45B derived: sum of 2 quarters · filed 2011-10-27 | -$102.00M 10-Q · filed 2011-10-27 | $1.21B derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $783.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | -$1.76B 10-Q · filed 2011-07-28 | -$449.00M derived: sum of 3 quarters · filed 2012-02-17 | -$1.59B derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | -$2.55B 10-Q · filed 2011-04-28 | -$1.23B derived: sum of 2 quarters · filed 2012-02-17 | -$2.37B derived: sum of 3 quarters · filed 2012-02-17 | -$2.70B derived: sum of 4 quarters · filed 2012-02-17 |
| 2009-12-31 | $1.32B derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $176.00M derived: sum of 2 quarters · filed 2012-02-17 | -$149.00M derived: sum of 3 quarters · filed 2012-02-17 | -$293.00M 10-K · filed 2012-02-17 |
| 2009-09-30 | -$1.14B derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | -$1.47B derived: sum of 2 quarters · filed 2010-10-26 | -$1.61B 10-Q · filed 2010-10-26 | -$806.00M derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-06-30 | -$325.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-22 | -$469.00M 10-Q · filed 2010-07-22 | $334.00M derived: sum of 3 quarters · filed 2011-02-18 | $3.46B derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-03-31 | -$144.00M 10-Q · filed 2010-04-29 | $659.00M derived: sum of 2 quarters · filed 2011-02-18 | $3.79B derived: sum of 3 quarters · filed 2011-02-18 | |
| 2008-12-31 | $803.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $3.93B derived: sum of 2 quarters · filed 2011-02-18 | $6.17B 10-K · filed 2011-02-18 | |
| 2008-09-30 | $3.13B derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-22 | $5.37B 10-Q · filed 2009-10-22 | ||
| 2008-06-30 | $2.25B 10-Q · filed 2009-07-23 | |||
| 2007-12-31 | -$217.00M 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |